Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search for
  Limits Preview/Index History Clipboard Details    
About Entrez
spacer gif
back to About Entrez
back to About Entrez

Text Version

Entrez PubMed
Help | FAQ

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries

Related Resources
Order Documents
NLM Gateway
Consumer Health
Clinical Alerts
PubMed Central

Privacy Policy


1: Hum Psychopharmacol. 2002 Jun;17(4):187-90. Related Articles, Links

Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia.

Stedman CA, Begg EJ, Kennedy MA, Roberts R, Wilkinson TJ.

Department of Clinical Pharmacology, Christchurch Hospital, Christchurch School of Medicine, Christchurch, New Zealand.

AIMS: The aims of this study were to determine if patients with SSRI-related hyponatraemia were (1) genetically poor metabolizers of CYP2D6, and/or (2) had excessive plasma concentrations of the SSRI antidepressant. METHODS: Plasma DNA from 20 people with hyponatraemia attributable to fluoxetine or paroxetine was analysed for the CYP2D6 alleles *1-*16. Trough plasma concentrations of fluoxetine and norfluoxetine, or paroxetine were assayed in nine people who remained on the antidepressant. RESULTS: Genotype results were compared with those published in a large population study. The poor metabolizer PM/PM genotype was present in one subject only, or 5% of the study population, compared with 7.2% of a general population. The 95% Cl of this result was 0-21%, suggesting that it is most unlikely that hyponatremia is related to the PM/PM genotype. The intermediate IM/PM genotype was present in 5% compared with 19.7% of a general population. All differences were not statistically significant. Antidepressant concentrations of fluoxetine (n = 5, all EM) and paroxetine (n = 1 IM/PM and n = 3 EM) were all within the lower half of the reference range. CONCLUSIONS: These results do not support the hypothesis that SSRI-related hyponatraemia is linked to genetically poor metabolizers, or excessive drug concentrations. Copyright 2002 John Wiley & Sons, Ltd.

Publication Types:
  • Clinical Trial

PMID: 12404686 [PubMed - indexed for MEDLINE]